Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 14/20 | 0.53 |
| ▸ | NOS3 | P29474 | 13/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 7/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6617566 | 0.88 | NOS1 (0.53) | NOS1NOS3CHRM2CHRM4HTR1A | |
| SCHEMBL6621671 | 0.88 | NOS1 (0.68) | NOS1NOS3CHRM2CHRM4HTR1A | |
| SCHEMBL6618478 | 0.86 | NOS1 (0.69) | NOS1NOS3CHRM2CHRM4HTR1A | |
| SCHEMBL6619268 | 0.86 | NOS1 (0.51) | NOS1NOS3CHRM2CHRM4NOS2 | |
| SCHEMBL6618730 | 0.83 | NOS1 (0.76) | NOS1NOS3CHRM2CHRM4HTR1A | |
| SCHEMBL6621871 | 0.75 | NOS1 (0.68) | NOS1NOS3CHRM2CHRM4HTR1A | |
| SCHEMBL6619303 | 0.74 | NOS1 (0.71) | NOS1NOS3CHRM2CHRM4HTR1A | |
| SCHEMBL7483828 | 0.72 | NOS1 (0.64) | NOS1NOS3CHRM2CHRM4SIGMAR1 | |
| SCHEMBL6620008 | 0.72 | NOS1 (0.74) | NOS1NOS3CHRM2CHRM4HTR1A | |
| SCHEMBL6622997 | 0.72 | NOS1 (0.67) | NOS1NOS3CHRM2CHRM4NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1471055-A1 | 6-phenylpyridyl-2-amine derivatives | PFIZER INC. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-0891332-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1109556-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000009130-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0891332-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036871-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | NOS1 3/4885NOS3 2/4885CHRM2 151/4885 |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | NOS1 1/4885NOS3 2/4885CHRM2 284/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS1 1/4885NOS3 2/4885CHRM2 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.